Mode
Text Size
Log in / Sign up

FGF/FGFR signaling systems provide diverse mechanistic targets across multiple systemic autoimmune rheumatic diseasesNew research maps potential targets for several autoimmune diseases

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that FGF/FGFR signaling provides multiple potential targets for RA, SLE, and other autoimmune rheumatic diseases.

This evidence-informed review synthesizes the roles of various FGF/FGFR signaling axes in systemic autoimmune rheumatic diseases, including Rheumatoid Arthritis (RA), Systemic Lupus Erythematem (SLE), Spondyloarthritis, and Sj"orren's Disease. The authors identify specific pathways with varying levels of support: FGF10/FGFR1 and FGF2/FGFR3 are linked to synovial fibroblast activation and bone erosion in RA; while the FGF23/Klotho axis is an emerging renal-metabolic biomarker for SLE and Lupus Nephritis.

In SSc-ILD, nintedanib demonstrates that FGFR-containing multi-kinase networks are clinically tractable, though the specific contribution of FGFR remains unresolved. For SpA and PsA, FGF2 and FGF7/FGFR2IIIb signaling are proposed as mechanisms for entheseal remodeling, but direct human validation is lacking. In Sj"orren's disease, FGF7/FGF10/FGFR2b signaling supports a regenerative hypothesis based on developmental biology.

The authors note that evidence for these pathways is scattered and unevenly supported. Specific gaps include the lack of direct human entheseal validation for SpA/PsA and unresolved FGFR-specific contributions in SSc-ILD. The review suggests that tissue-level validation, longitudinal biomarker studies, and short-course proof-of-mechanism trials are required before clinical translation.

How this fits prior evidence

This review addresses a gap in the mechanistic understanding of autoimmune diseases by identifying specific FGF/FGFR signaling pathways. While prior coverage highlighted integrated biomarker panels to identify synovial endotypes in RA, this review provides specific molecular targets like FGF10/FGFR1 for synovial fibroblast activation. It also explores potential target therapies such as succinate-related pathways and extracellular vesicles mentioned in previous coverage, while focusing on the distinct roles of FGF signaling in diverse conditions like Sj"orren's disease and SSc-ILD.

Living with an autoimmune disease means dealing with constant inflammation and tissue damage. New research is looking closely at the FGF signaling system, a group of proteins that play a major role in how our bodies repair tissues and build bone. This work helps map out specific pathways that could one day lead to better treatments for conditions like rheumatoid arthritis and Sjögren's disease.

The review looked at several different conditions, including lupus nephritis and psoriatic arthritis. For example, researchers found that certain proteins might be linked to bone erosion in rheumatoid arthritis and kidney inflammation in lupus. While some of these findings are based on how cells behave in a lab, they provide a roadmap for what scientists should study next.

It is important to note that much of this evidence is still early and unevenly supported. For instance, while certain proteins show promise for treating lung disease, the exact role of specific receptors is not yet clear. Because these findings are currently based on research models rather than large human trials, they represent a starting point for future medical development.

What this means for you:
New research identifies specific protein pathways that could eventually help treat various autoimmune conditions.

Common questions

What specific conditions does this research cover?

The review covers several autoimmune conditions, including Rheumatoid Arthritis, Systemic Lupus Erythematosus (including Lupus Nephritis), Systemic Sclerosis, Spondyloarthritis, Psoriatic Arthritis, and Sjögren's Disease.

Is this a new treatment for my condition?

No, this is not a new treatment. The research identifies biological pathways and markers that could lead to future treatments. Because the evidence is currently scattered and some parts are not yet fully understood, you should talk to your doctor about current treatment options.

What are the limitations of these findings?

The evidence for these protein pathways is currently scattered and unevenly supported. For example, certain mechanisms for psoriatic arthritis lack direct human validation, and the specific role of some receptors in lung disease remains unresolved.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
The fibroblast growth factor (FGF)/FGF receptor (FGFR) signaling system regulates tissue repair, angiogenesis, extracellular matrix remodeling, fibrosis, and bone metabolism. Although FGF/FGFR biology has been extensively studied in oncology, development, and fibrotic lung disease, its relevance to systemic autoimmune rheumatic diseases remains scattered across disease-specific and unevenly supported literatures. This narrative, evidence-informed review synthesizes current evidence on FGF/FGFR signaling in rheumatoid arthritis (RA), systemic lupus erythematosus/lupus nephritis (SLE/LN), systemic sclerosis (SSc), spondyloarthritis/psoriatic arthritis (SpA/PsA), and Sjögren’s disease. We explicitly distinguish mechanistically supported axes from biomarker-level associations and extrapolated regenerative concepts. In RA, FGF10/FGFR1 and FGF2/FGFR3 have the strongest tissue-level support, linking relapse-prone synovial fibroblast niches, fibroblast-like synoviocyte activation, angiogenesis, and bone erosion. In SLE/LN, FGF23/Klotho is best interpreted as an emerging renal-metabolic and inflammatory biomarker axis rather than a validated therapeutic target, although reported associations with urinary MCP-1/CCL2 suggest testable links to renal chemokine-mediated inflammation. In SSc-ILD, nintedanib demonstrates that FGFR-containing multi-kinase networks are clinically tractable, but the FGFR-specific contribution remains unresolved. In SpA/PsA, FGF2-mediated angiogenesis-osteogenesis coupling and FGF7/FGFR2IIIb signaling provide candidate mechanisms for entheseal remodeling, whereas direct human entheseal validation is still lacking. In Sjögren’s disease, FGF7/FGF10/FGFR2b signaling supports a regenerative hypothesis derived mainly from salivary gland developmental biology and organoid studies. We propose an axis-prioritization translational framework that specifies ligand-receptor pairs, patient subgroups, validation tissues, delivery strategies, pharmacodynamic endpoints, and clinical or imaging readouts. This review is not a systematic review or meta-analysis; rather, it provides a structured roadmap for tissue-level validation, longitudinal biomarker studies, and short-course proof-of-mechanism trials before clinical translation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.